What is the impact of ejection fraction on NT-proBNP testing?
The committee acknowledged that a substantial majority of the patients in the included studies had HFREF (heart failure with reduced ejection fraction). Because the committee agreed that NP monitoring would have greatest benefit as part of a treatment optimisation protocol, and there was no evidence for long term prognostic benefit from pharmaceutical treatment in HFPEF (heart failure with preserved ejection fraction), it was unlikely that patients with HFPEF would receive significant benefit from NP monitoring. This aligned with subgroup analyses reported in the existing meta-analyses, which showed that the mortality and all- cause hospitalisation benefit of NP monitoring was found in HFREF but not HFPEF patients.